The Savory Journey of the New Sweetness: 4 takeaways from the Amyris acquisition of Oobli

November 16, 2026 |

Sweetness is one of life’s simplest pleasures. Making it, however, has become hard and complex yakka. Last week, Amyris announced plans to acquire Oobli, the California pioneer of sweet proteins, in a transaction that brings together two generations of industrial biotechnology. Terms were not disclosed, and closing is expected in the coming weeks.

Oobli’s remarkable molecules, including brazzein, monellin and thaumatin, are hundreds to thousands of times sweeter than sugar. They activate sweetness receptors on the tongue, yet are digested as proteins rather than sugars. Oobli produces them through precision fermentation instead of extracting them from rare tropical fruits. It sounds like a sweet deal. And it may be. But the real story is more savory: four developments that tell us something important about how the bioeconomy is learning to organize itself. Here are our four top-line takeaways:

1. Amyris discovers a new protein frontier

Amyris knows a thing or two about making molecules. Its industrial history includes farnesene, fragrances, specialty chemicals and fermentation-derived Reb M, the prized stevia sweetener now commercialized by Ingredion. But proteins are another frontier.

Oobli brings specialized expertise in producing sweet proteins, expanding Amyris’s potential capabilities beyond its established portfolio of smaller molecules. Proteins present distinctive challenges in expression, folding, purification, stability and formulation. For Amyris CEO Kathy Fortmann, the attraction extends beyond sweetness. Protein and peptide applications could eventually reach personal care, flavors and fragrances, agriculture and other markets. The company that emerged from bankruptcy in 2024 with a renewed B2B focus isn’t just adding stainless steel—it’s adding a new biological operating system alongside its small-molecule engine.

2. Oobli discovers that scale is more than fermentation

Oobli has already traveled a considerable distance. Founded in 2014, it has developed a portfolio of sweet proteins, secured important FDA no-questions GRAS responses for brazzein and monellin, raised nearly $60 million, and established relationships with major food companies.

What does Amyris add? Industrial experience, strain engineering, process development, manufacturing resources and commercial reach. But here comes the interesting twist. Amyris does not immediately intend to transfer Oobli production to its Barra Bonita plant in Brazil. Fortmann has indicated that existing contract manufacturing relationships will continue as production scales. Industrial scale is not simply owning the biggest fermenter. It is organizing reliable production, downstream processing, quality, delivery and commercial relationships. And a sweet protein is not yet a successful sugar replacement simply because it is extraordinarily sweet. Sugar also supplies bulk, texture, browning, preservation and other functions. Replacing its sweetness while making its other jobs ruinously expensive is not a commercial breakthrough.

The real test comes in the formulation.

3. Ingredion may hold an important piece of the puzzle

Here the story becomes particularly intriguing. Ingredion already has relationships with both companies.

Amyris developed fermentation-derived Reb M technology that Ingredion now has exclusive rights to manufacture and commercialize under arrangements revised in 2025. Amyris retains a royalty interest, while regaining full ownership of its Brazilian fermentation plant. Separately, Ingredion Ventures invested in Oobli, and the two companies established a partnership in February 2025 to develop sweetener systems combining Oobli proteins with stevia.

Why does that matter?

Because customers don’t buy molecules merely because scientists can produce them. They buy ingredients that are available, effective and applicable in real products. That makes formulation, sensory science, applications development and global ingredient distribution central to the economics. Ingredion’s existing relationships may provide important commercial connections as Amyris and Oobli come together. No new three-way arrangement has been announced, but the possibilities are evident. The sweetener may supply the activation. The formulator supplies the solution.

4. The remarkable circulation of talent, capital and knowledge

There’s a final twist.

Oobli co-founder Jason Ryder previously held a senior technical role at Amyris. He went on to work at Bolt Threads and Hampton Creek before helping build the sweet protein venture that Amyris now proposes to acquire. Meanwhile, Oobli’s financial backers have included Khosla Ventures, Piva Capital, B37 Ventures, Ingredion Ventures and others. It’s a relatively small industrial world, with familiar investors, engineers, entrepreneurs and commercial partners appearing in new combinations.

Not all the capital survives. Amyris’s bankruptcy demonstrated that painfully. Companies fail, investors lose money, and technologies sometimes disappear. But industrial knowledge is remarkably mobile. People carry it from one enterprise to another. Partnerships outlast particular corporate structures. Manufacturing lessons learned at great expense become the foundation of new ventures. And sometimes the people who leave a company return with something that company now needs.

The end of the beginning

There’s a Rockefeller impulse in the Amyris–Oobli acquisition: the recognition that bringing complementary capabilities together can create more value than leaving them scattered. In this way, in the industrial biotechnology we have arrived perhaps to the 1870s. So, this is still early days. But perhaps this is the end of the beginning.

The prize is not simply a larger collection of molecules or fermentation assets. It is the possibility of connecting invention, production, formulation and markets into a more productive industrial system. Whether this particular combination succeeds remains to be seen. The economics of production, customer adoption and repeat commercial sales will have the final word.

The larger lesson is already visible: The molecule is only the beginning. The ingredient is the achievement. The organized industrial system is what makes the achievement repeatable. But concentration is only half the story. In our companion Digest essay, we explore what happens when industrial capabilities diffuse beyond the companies that first brought them together—and why the greatest achievement may be organizing a system without owning it.

Category: Top Stories

Thank you for visting the Digest.

}